Erratum
Unfortunately, after publication of this article [1], it was noticed that the name of Gianfranco Ferraccioli was incorrectly spelled as Gianfranco Ferraciolli. The corrected author list can be seen above and the original article has been updated to correct this error.
Reference
Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294. http://doi.org/10.1186/s13075-016-1190-z.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The online version of the original article can be found under doi:10.1186/s13075-016-1190-z.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Sellam, J., Rivière, E., Courties, A. et al. Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther 19, 11 (2017). https://doi.org/10.1186/s13075-017-1221-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13075-017-1221-4